Clinical Trial Update: A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial to identify an optimal dose of QCZ484 in adults with mild to moderate hypertension is currently recruiting, sponsored by Novartis Pharmaceutical…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• QCZ484

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Hypertension | Phase 2 | Status: RECRUITING